Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multicenter Study In Patients With Type 2 Diabetes And Persistent Albuminuria To Evaluate The Safety And Efficacy Of A Six Month Regimen Of Orally-Administered TTP488.

Trial Profile

Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multicenter Study In Patients With Type 2 Diabetes And Persistent Albuminuria To Evaluate The Safety And Efficacy Of A Six Month Regimen Of Orally-Administered TTP488.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2011

At a glance

  • Drugs Azeliragon (Primary)
  • Indications Diabetic nephropathies; Proteinuria; Type 2 diabetes mellitus
  • Focus Biomarker; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Jul 2011 Primary endpoint 'Urinary-albumin:creatinine-ratio' has not been met, as reported in abstract from 71st Annual Scientific Sessions of the American Diabetes Association.
    • 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
    • 06 Oct 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top